Oppenheimer Holdings, Inc. began coverage on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a research report released on Tuesday, July 18th. The firm issued a market perform rating on the stock. Oppenheimer Holdings also issued estimates for Intellia Therapeutics’ Q2 2017 earnings at ($0.39) EPS, Q3 2017 earnings at ($0.44) EPS, Q4 2017 earnings at ($0.47) EPS, FY2017 earnings at ($1.66) EPS, Q1 2018 earnings at ($0.51) EPS, Q2 2018 earnings at ($0.55) EPS, Q3 2018 earnings at ($0.55) EPS, Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($2.19) EPS, FY2019 earnings at ($3.50) EPS, FY2020 earnings at ($4.77) EPS and FY2021 earnings at ($3.74) EPS.
A number of other research firms have also weighed in on NTLA. Cann reiterated a market perform rating on shares of Intellia Therapeutics in a research note on Monday, July 17th. Credit Suisse Group set a $24.00 price target on shares of Intellia Therapeutics and gave the company a buy rating in a report on Wednesday, May 3rd. Wedbush reissued an outperform rating and issued a $25.00 price target on shares of Intellia Therapeutics in a report on Monday, May 15th. TheStreet raised shares of Intellia Therapeutics from a d+ rating to a c- rating in a report on Thursday, July 6th. Finally, Chardan Capital assumed coverage on shares of Intellia Therapeutics in a report on Monday, March 27th. They issued a buy rating and a $19.00 price target for the company. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $25.86.
Shares of Intellia Therapeutics (NTLA) opened at 16.10 on Tuesday. Intellia Therapeutics has a one year low of $10.83 and a one year high of $24.90. The stock’s 50 day moving average price is $15.83 and its 200 day moving average price is $14.14. The stock’s market capitalization is $581.40 million.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. The company’s revenue for the quarter was up 40.5% on a year-over-year basis. On average, analysts forecast that Intellia Therapeutics will post ($1.74) EPS for the current year.
In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 12.80% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its stake in Intellia Therapeutics by 6.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 26,903 shares of the company’s stock valued at $380,000 after buying an additional 1,539 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Intellia Therapeutics by 5.6% in the first quarter. Bank of New York Mellon Corp now owns 31,676 shares of the company’s stock worth $446,000 after buying an additional 1,682 shares during the last quarter. Geode Capital Management LLC boosted its position in Intellia Therapeutics by 6.0% in the first quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock worth $1,072,000 after buying an additional 4,291 shares during the last quarter. SG Americas Securities LLC purchased a new position in Intellia Therapeutics during the second quarter worth about $101,000. Finally, Bank of Montreal Can boosted its position in Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares during the last quarter. 46.99% of the stock is owned by institutional investors and hedge funds.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
